<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829257</url>
  </required_header>
  <id_info>
    <org_study_id>PAW01</org_study_id>
    <secondary_id>Eudract no: 2008-001811-40</secondary_id>
    <nct_id>NCT00829257</nct_id>
  </id_info>
  <brief_title>Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma</brief_title>
  <acronym>PAW01</acronym>
  <official_title>A Proof of Concept Study to Evaluate the Additive Effects of HFA-BDP (Qvar) to Fluticasone/Salmeterol (Seretide) on Surrogate Markers of Small and Large Airway Inflammation in Refractory Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish whether addition of extra-fine particle steroid
      inhalers achieve additional suppression of small airways inflammation when added to
      'standard' Fluticasone/Salmeterol combination therapy in refractory asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alveolar nitric oxide</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fine particle steroid inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFA-BDP plus Fluticasone/Salmeterol Combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coarse Particle Inhaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FP plus Fluticasone/Salmeterol combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HFA-BDP</intervention_name>
    <description>HFA-BDP (Qvar) 100ug 2puff b.i.d</description>
    <arm_group_label>Fine particle steroid inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>Fluticasone propionate Accuhaler 250ug b.i.d.</description>
    <arm_group_label>Coarse Particle Inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide</intervention_name>
    <description>Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d</description>
    <arm_group_label>Coarse Particle Inhaler</arm_group_label>
    <arm_group_label>Fine particle steroid inhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory, non-smoking asthmatics with FEV1 les than 80% predicted

          -  RV greater than 100% predicted and CANO greater than 3ppb when stepped up to 1000Âµg of
             fluticasone per day, with or without additional asthma medication.

          -  Informed consent and ability to perform exhaled nitric oxide assessment.

          -  Participants must be on greater than 500mcg of fluticasone per day to enter dose ramp
             run-in.

        Exclusion Criteria:

          -  Recent respiratory infection or oral steroid use.

          -  Pregnancy or lactation.

          -  Known or suspected contra-indication to any of the IMP's.

          -  CANO less than 3ppb, FEV1 greater than 80% or RV less than 100% at post-optimisation
             visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Williamson</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma and Allergy Research Group, Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Williamson PA, Short PM, Vaidyanathan S, Lipworth BJ. Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy. Br J Clin Pharmacol. 2013 Jan;75(1):93-102. doi: 10.1111/j.1365-2125.2012.04319.x.</citation>
    <PMID>22568828</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Brian J Lipworth</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fluticasone-Salmeterol Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

